Equities

Haw Par Corporation Ltd

Haw Par Corporation Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SGD)11.17
  • Today's Change-0.01 / -0.09%
  • Shares traded24.10k
  • 1 Year change+13.17%
  • Beta0.6388
Data delayed at least 10 minutes, as of Nov 22 2024 09:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SGD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments574334596
Total Receivables, Net492733
Total Inventory191913
Prepaid expenses------
Other current assets, total------
Total current assets642381642
Property, plant & equipment, net505032
Goodwill, net111111
Intangibles, net000
Long term investments2,8883,2052,594
Note receivable - long term------
Other long term assets------
Total assets3,5933,6503,284
LIABILITIES
Accounts payable3.913.543.34
Accrued expenses------
Notes payable/short-term debt28290
Current portion long-term debt/capital leases------
Other current liabilities, total846867
Total current liabilities11610070
Total long term debt0.640.700.76
Total debt28290.76
Deferred income tax0.760.910.89
Minority interest------
Other liabilities, total------
Total liabilities11710172
SHAREHOLDERS EQUITY
Common stock269269269
Additional paid-in capital------
Retained earnings (accumulated deficit)1,4421,3031,221
Treasury stock - common------
Unrealized gain (loss)1,7731,9801,721
Other equity, total(7.82)(3.39)0.67
Total equity3,4763,5493,211
Total liabilities & shareholders' equity3,5933,6503,284
Total common shares outstanding221221221
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.